tweetindex
EN

dough ✓

@semodough · joined 02 Sep 2015

BIOTECH man LONGTERM FOCUS many positions-also trade around my CORE holdings my opinion only do your own research with me

44 255Followers
638Following
82 178Posts total
44.3KViews on collected posts

Latest posts

$VERA $XBI #Biotech another Strong BIOTECH commercial launch momentum with over 350 patient start forms generated in the first ten weeks. 6.3K views · 25 likes · 0 reposts · 3 replies Open on X →
$ROIV Cantor Quick Take/$ROIV: Three Drugs with $5-10B Peak Sales Potential Each $IMVT 4.2K views · 11 likes · 0 reposts · 3 replies Open on X →
$OCUL @Baird fireside sept 15 1050-1120 am EDT 4.2K views · 9 likes · 0 reposts · 1 replies Open on X →
$OCUL Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission 7.4K views · 12 likes · 3 reposts · 2 replies Open on X →
$OCUL Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD | Ocular Therapeutix, Inc. https://t.co/YdFAGdnoIr 11.3K views · 12 likes · 4 reposts · 1 replies Open on X →
@semodough Still this bullish with sibe leading the pack in B-cell modulators and pove right behind ataci? Dosing and convenience also favor sibe/pove>ataci 221 views · 1 likes · 0 reposts · 0 replies Open on X →
@semodough Mate, the revenue math makes VERA look seriously undervalued at current levels. 206 views · 0 likes · 0 reposts · 0 replies Open on X →
$VERA Cantor continue to view VERA shares as undervalued (~$2.3B mkt cap with $499M in cash as of 2Q26), given Trutakna’s competitive profile in IgAN and a >$20B market that can easily accommodate multiple disease-modifying B cell modulators. math suggests IgAN patients with 10.5K views · 12 likes · 0 reposts · 4 replies Open on X →
Wonderful Day for me. - celebrating 25 GREAT years with my WIFE & best friend today. Best decision I ever made - happy #anniversary to my WIFE ❤️❤️ https://t.co/cuTGSePQAP
0 views · 865 likes · 16 reposts · 55 replies Open on X →
Tomorrow 23 year anniversary +8 years of dating -like @SheffStation I started young 😃 MY WIFE best #LONGTERM Decisions I ever made ❤️❤️❤️ https://t.co/KG6zSun8GC 0 views · 130 likes · 1 reposts · 17 replies Open on X →

Against accounts of the same size

8 posts from the last 90 days, next to the 10K–100K follower range. shown widely, but few of those viewers react.

Median views5 274this account992median for 10K–100K
Reach, %11.92%this account3.89%median for 10K–100K
Engagement, %0.24%this account1.54%median for 10K–100K
MetricThis accountMedian for 10K–100KRatio
Median views per post5 2749925.32×
Reach (views ÷ followers)11.92%3.89%3.06×
Engagement rate0.24%1.54%0.16×

Others in this range →   Compare with another account →   How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

10.5K11 Aug
206
221
11.3K15 Sep
7.4K
4.2K
4.2K
6.3K

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.16%11 Aug
0.00%
0.45%
0.17%15 Sep
0.24%
0.24%
0.34%
0.44%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.54%.

What the audience does

Likes68.9%82 in total
Reposts5.9%7 in total
Replies11.8%14 in total
Quotes3.4%4 in total
Bookmarks10.1%12 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Similar accounts